Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.77M P/E - EPS this Y 50.00% Ern Qtrly Grth -
Income -22.76M Forward P/E -0.18 EPS next Y -82.10% 50D Avg Chg -4.00%
Sales 420k PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.77 EPS next 5Y - 52W High Chg -74.00%
Recommedations 2.00 Quick Ratio 0.77 Shares Outstanding 1.32M 52W Low Chg 24.00%
Insider Own 7.12% ROA -86.33% Shares Float 1.14M Beta 0.57
Inst Own 16.73% ROE -272.63% Shares Shorted/Prior 38.41K/26.61K Price 0.62
Gross Margin 100.00% Profit Margin - Avg. Volume 71,251 Target Price 16.00
Oper. Margin -17,290.32% Earnings Date May 9 Volume 24,738 Change 0.98%
About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Cyclacel Pharmaceuticals, Inc. News
04/25/24 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
04/01/24 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
03/20/24 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
03/19/24 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/13/24 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
03/07/24 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/06/24 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
02/20/24 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
01/30/24 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
01/08/24 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
01/02/24 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
12/22/23 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
12/18/23 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
12/12/23 Cyclacel Pharmaceuticals Announces Reverse Stock Split
11/30/23 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
11/28/23 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
11/14/23 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
11/13/23 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
11/07/23 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
08/10/23 Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call
CYCC Chatroom

User Image LookaLike Posted - 16 hours ago

$CYCC float traded 3 times on Thursday. Watch out

User Image illumantistocks Posted - 22 hours ago

$CYCC JUNE 3rd folks!!! will the day I drop this bloody bag, I lost so much I can not just sell and lose it all.

User Image intratio Posted - 22 hours ago

https://www.intratio.com/stock-forecast/CYCC Our engine is forecasting this stock s value will increase during the next few days and the stock price is in line with the long-term fundamentals of the business $CYCC

User Image illumantistocks Posted - 1 day ago

$AIRE I will buy back in on monday just sold taking the loss from 1.60 when I got in. Not going to back hold on this one. I am going to however bag hold for $CYCC in which i am 6k down as of today and I will continue to bag hold till JUNE 3rd on this pup.

User Image illumantistocks Posted - 1 day ago

$CYCC just wait for JUNE 3rd then you can through me under the buss as per usual okay bud.

User Image casedoog Posted - 1 day ago

$CYCC how are they going to dilute 16 million shares when this trashy stock is only trading 100,000 shares??

User Image illumantistocks Posted - 1 day ago

$CYCC ITS GOING TO TAKE TIME< JUST LOAD AND FORGET, JUNE is a while off I know but once we get the data this goes PARABOLIC mark this post. Its a nice play if you can just hold till JUNE 3rd folks.

User Image illumantistocks Posted - 1 day ago

$CYCC that's fine let's put this dog down but wait till after June 5th!!!! then do what you want. I am telling you this DATA is ground breaking and this pup has too much riding on it not to pump again. Its a given load up as much as you can until then.

User Image MikeEhrmantraut Posted - 1 day ago

$CYCC This dog needs to be put down. It’s old, blind, with severe dysplasia and has never been the least bit friendly or loyal to owners.

User Image illumantistocks Posted - 1 day ago

$CYCC We are going to rally up and down from 2.07 to 1.70 and so on and so forth till we get the data it's a given. If you want the big money you have to load and hold till JUNE 3rd minimum

User Image illumantistocks Posted - 1 day ago

$CYCC My sell is set to 8.50 USD for 90 days and I am holding till June 3rd. Yes June 3rd if I am still 5k down I will sell but I am giving her to June 3rd that is a given.

User Image LookaLike Posted - 1 day ago

$CYCC short interest anyone?

User Image Marypennsylvanialand Posted - 1 day ago

$CYCC the patient is dead again, there is no pulse. Toes up...

User Image BarbaraStein Posted - 1 day ago

$CYCC cover before Friday close AH ++ OCEA too both big short positions

User Image Kassianys Posted - 1 day ago

$CYCC consolidation zone for next leg 2$+ !

User Image WallStMoneyMaker Posted - 1 day ago

$CYCC Easy climb back to $2+

User Image oklahoma6 Posted - 1 day ago

$CYCC so what are we looking at for PT Today

User Image Rounderssss4 Posted - 1 day ago

$CYCC looks like over kill here👀

User Image oklahoma6 Posted - 1 day ago

$CYCC 1.80 today

User Image Phil_Hertits Posted - 1 day ago

$CYCC I'm sure you're up massively here right, pickle smoocher?

User Image Phil_Hertits Posted - 1 day ago

$CYCC this trash has been cross-posted on every board by pumpers for days. 😂😂😂

User Image Shariegrl Posted - 1 day ago

$CYCC why is this down so much?

User Image johntwit88 Posted - 1 day ago

$CYCC wow..juicy dip..loaddddddd

User Image elmono Posted - 1 day ago

$CYCC thxs for cheapies…wonder whose stop got triggered 😂😂😂

User Image elmono Posted - 1 day ago

$CYCC and not to forget, company touting: “ Thank you, operator, and thanks to all of you for joining Cyclacel’s third quarter earnings call. Both our programs are approaching important catalysts such as starting Phase II proof-of-concept stage with a strong competitive profile in their therapeutic classes. As a reminder, our upcoming key milestones are: report final data from dose escalation stage and the RP2D determination from the 065-101 study of oral fadra in patients with advanced solid tumors and lymphoma; first patient dosed with oral fadra in Phase II stage of 065-101 study in patients with advanced solid tumors and lymphoma; report Phase I data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma; and elaborate the novel mechanism of action of plogo. We look forward to providing you with further updates and hope to meet some of you at upcoming conferences. Operator, at this time, you may end the call.” All key milestones soon….😏

User Image elmono Posted - 1 day ago

$CYCC what I am waiting for, from last Q&A in 2023 “ Thank you for your question, Ahu. These are known biomarkers in terms of appearance on next-gen sequencing, scans and past reports and so forth. However, they are novel for the CDK class. We believe we’ve made a discovery that has not been reported previously for this class, and we think that there is sufficient clinical support for these hypothesis to be pursued further in the clinic. Disclosure should occur, as we said, when we give the full Phase I update. We’re obviously hoping to present this data at upcoming medical meetings, and that will be important as far as deadlines are concerned as to when we made the announcement. But I would expect probably around the end of the year or early next year.”

User Image elmono Posted - 1 day ago

$CYCC accumulation mode….data coming in a few weeks

User Image driv300mph Posted - 1 day ago

$CYCC so was this just one of those Discord pump n dumps?

User Image StockScanners Posted - 1 day ago

$CYCC We reached 4.05!, what a sell off though

User Image illumantistocks Posted - 1 day ago

@casedoog Get in on $CYCC for JUNE 1st thats my big one now. Target is 9 :)

Analyst Ratings
Brookline Capital Hold Dec 19, 23
Roth MKM Buy Dec 19, 23